Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pierre Fabre
In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.
Novartis, Arvelle, AstraZeneca and Incyte are among a raft of drug sponsors who should find out shortly whether the European Medicines Agency will vote in favor of approving their products for use in the EU.
Former Ignyta CEO’s well-funded Erasca obtained its first clinical-stage precision oncology candidates from NiKang and Asana, eyeing a first-in-class approach to RAS/MAPK-driven cancers.
2020 has kicked off with a major European biotech deal that will see the Italian conglomerate Angelini take over Switzerland's Arvelle which is on the verge of getting EU approval for an anti-epilepsy drug licensed from SK Bio that got the green light in the US two years ago.
- Pharmacy Services, PBMs
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Pierre Fabre Medicament S.A.